One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensitive prostate cancer with high tumor load.
Phase 3 – large-scale trial before approval
Conditions:
Metastatic hormone-sensitive prostate cancer with high tumor load
Sponsor: Jiangsu Hengrui Pharmaceuticals Co. Ltd.
trial.available_in:
БГ
Overview
Trial status: Authorised
Time to PSA progression., Time to the next bone related event (including fracture, spinal compression, radiotherapy or surgery for bones)., Time to the start of the next anti-prostate cancer treatment., ORR, Safety endpoint.
rPFS,OS
Description
Time to PSA progression., Time to the next bone related event (including fracture, spinal compression, radiotherapy or surgery for bones)., Time to the start of the next anti-prostate cancer treatment., ORR, Safety endpoint.
Who can participate
Age group: 18-64 years, 65+ years
Gender: Male
Target enrollment: 63 participants
БГ